E3 PreliminaryPreliminaryPEM ?Case-ControlPeer-reviewedMachine draft
Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19-associated chronic fatigue syndrome.
Kerr, J R, Cunniffe, V S, Kelleher, P et al. · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2003 · DOI
Quick Summary
This study looked at three patients whose chronic fatigue syndrome (ME/CFS) appeared to start after they were infected with parvovirus B19, a common virus. These patients were treated with intravenous immunoglobulin (IVIG), a therapy that contains antibodies from donated blood. All three patients improved significantly, with their symptoms resolving and their ability to function returning to normal.
Why It Matters
This study is significant because it suggests that some cases of ME/CFS may be triggered by persistent parvovirus B19 infection and that a specific, directed treatment might be effective in these cases. The improvement in both symptoms and immune markers raises important questions about whether viral persistence and immune dysregulation are mechanistic factors in at least a subgroup of ME/CFS patients.
Observed Findings
- All three patients experienced clearance of parvovirus B19 viremia following IVIG treatment
- Complete symptom resolution was achieved in all three treated patients
- Physical and functional ability improved in all three patients
- Cytokine and chemokine dysregulation normalized following successful treatment
Inferred Conclusions
- Persistent parvovirus B19 infection may be responsible for ME/CFS symptoms in some patients
- IVIG therapy may be an effective treatment for parvovirus B19-associated ME/CFS
- Immune dysregulation in these cases may be secondary to viral persistence rather than a primary immune abnormality
Remaining Questions
- What proportion of ME/CFS patients actually have underlying parvovirus B19 infection?
- Would IVIG be effective in patients with CFS who test positive for parvovirus B19 but have already had prolonged illness?
- What are the mechanisms by which parvovirus B19 establishes persistent infection in some individuals but not others?
- Are there predictive markers that could identify which ME/CFS patients would benefit most from IVIG therapy?
What This Study Does Not Prove
This study does not prove that parvovirus B19 causes ME/CFS in the general patient population, as it only describes three cases. It does not establish that IVIG would be effective for ME/CFS patients without documented parvovirus B19 infection, nor does it determine whether the improvement was due to IVIG's antiviral properties, its immune-modulating effects, or another mechanism. The lack of a control group means we cannot definitively attribute outcomes to the treatment rather than natural recovery.
Tags
Symptom:Fatigue
Biomarker:Cytokines
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall Sample
Metadata
- DOI
- 10.1086/374666
- PMID
- 12715326
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026